.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Teva
Johnson and Johnson
Covington
UBS
US Department of Justice
AstraZeneca
Dow
Julphar
Novartis

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,340,695

« Back to Dashboard

Which drugs does patent 6,340,695 protect, and when does it expire?


Patent 6,340,695 protects DICLEGIS and is included in one NDA. There has been one Paragraph IV challenge on Diclegis.

This patent has forty-nine patent family members in thirty-six countries.

Summary for Patent: 6,340,695

Title: Rapid onset formulation
Abstract:Provided herein is a novel enterically-coated pyridoxine HCl and doxylamine succinate rapid onset formulation comprising a disintegrating agent such that the following dissolution profiles are satisfied when measured in 1000 ml phosphate buffer at pH 6.8 and 37.degree. C. in a type 2 dissolution apparatus at 100 rpm: (a) at least about 40% of the total pyridoxine HCl and doxylamine succinate is dissolved after 30 minutes of measurement; (b) at least about 70% of the total pyridoxine HCl and doxylamine succinate is dissolved after 60 minutes of measurement; (c) at least about 80% of the total pyridoxine HCl and doxylamine succinate is dissolved after 90 minutes of measurement; (d) at about 90% of the total pyridoxine HCl and doxylamine succinate is dissolved after 120 minutes of measurement. Preferably the formulation will contain a core coated with at least one enteric coating, the core comprising pyridoxine HCl, doxylamine succinate and the following non-active excipients: a filler or binder, a disintegrating agent, a lubricant, a silica flow conditioner and a stabilizing agent.
Inventor(s): Gervais; Eric (Laval, CA)
Assignee: Duchesnay Inc. (Laval, CA)
Application Number:09/885,051
Patent Claim Types:
see list of patent claims
Formulation; Compound; Device; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Duchesnay
DICLEGIS
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► SubscribeY TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,340,695

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20022982► Subscribe
Netherlands1020895► Subscribe
MexicoPA02006037► Subscribe
Monaco200059► Subscribe
Luxembourg90934► Subscribe
South Korea100527985► Subscribe
South Korea20030023612► Subscribe
Japan4242763► Subscribe
Japan2004521146► Subscribe
ItalyTO20020524► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Deloitte
Baxter
Federal Trade Commission
Citi
Fish and Richardson
US Department of Justice
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot